Correlation between urinary levels of isoprostane F2α-VI (iPF2α-VI) in the subjects investigated and their age (r2 = 0.05, P = .18).
A, Urinary levels of 2,3-dinor-thromboxane B2 (2,3-dinor-TxB2) in subjects with autism and control subjects. B, Urinary levels of 6-keto-prostaglandin F1α (6-keto-PGF1α) in subjects with autism and control subjects. Asterisk indicates P<.01; horizontal lines, means.
Correlation between urinary levels of isoprostane F2α-VI (iPF2α-VI) with 2,3-dinor-thromboxane B2 (2,3-dinor-TxB2) (P=.003) (A) iPF2α-VI with 6-keto-prostaglandin F1α (6-keto-PGF1α) (P=.002) in subjects with autism (B).
Customize your JAMA Network experience by selecting one or more topics from the list below.
Yao Y, Walsh WJ, McGinnis WR, Praticò D. Altered Vascular Phenotype in AutismCorrelation With Oxidative Stress. Arch Neurol. 2006;63(8):1161–1164. doi:10.1001/archneur.63.8.1161
Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Autism is a neurologic disorder characterized by impaired communication and social interaction. Results of previous studies showed biochemical evidence for abnormal platelet reactivity and altered blood flow in children with autism.
To evaluate the vascular phenotype in children with autism.
Design and Main Outcome Measures
Urinary levels of isoprostane F2α-VI, a marker of lipid peroxidation; 2,3-dinor-thromboxane B2, which reflects platelet activation; and 6-keto-prostaglandin F1α, a marker of endothelium activation, were measured by means of gas chromatography-mass spectrometry in subjects with autism and healthy control subjects.
Setting and Subjects
Children with a clinical diagnosis of autism attending the Pfeiffer Treatment Center.
Compared with controls, children with autism had significantly higher urinary levels of isoprostane F2α-VI, 2,3-dinor-thromboxane B2, and 6-keto-prostaglandin F1α. Lipid peroxidation levels directly correlated with both vascular biomarker ratios.
Besides enhanced oxidative stress, platelet and vascular endothelium activation also could contribute to the development and clinical manifestations of autism.
Autism is a neurologic disorder with typical onset before the age of 3 years and is characterized by impairments in social, behavioral, and communicative functions.1 The condition is highly prevalent, and in recent years there has been an apparent increase in the diagnosis of this disorder.2 Although the biological basis for autism remains unknown, there is increasing evidence that genetic, environmental, and immunologic factors could contribute to its development.3-5
Several lines of emerging evidence suggest a potential role for enhanced oxidative stress in autism. Thus, increased levels of nitric oxide have been reported in individuals with autism in association with markers of lipid peroxidation, which would suggest excessive reactive oxygen species formation.6 Moreover, there are reports of alteration in energy metabolism, possibly linked to mitochondrial dysfunction, and a significant reduction in endogenous antioxidants in autism compared with that in control subjects.7-9 Recent research results indicate that the F2-isoprostane 8-iso-prostaglandin F2α is enhanced in children with autism.10 This isoprostane is a nonenzymatic oxidation product of arachidonic acid and is widely recognized as a reliable marker of lipid peroxidation. Moreover, it induces in vivo vasoconstriction and amplifies agonist-induced platelet adhesion and aggregation.11 Thus, the enhanced formation of biologically active F2-isoprostane in this syndrome also could result in platelet and vascular activation. Previous study results indicated indirect biochemical evidence for altered platelet reactivity in autism, and most of the work has been focused on serotonin and its receptor in platelets.12 However, no data are available regarding systemic platelet activation as reflected by levels of 2,3-dinor-thromboxane (Tx)B2, the stable metabolite of the platelet cyclooxygenase-derived TxA2.13 The same consideration is valid for markers of vascular activation as reflected by 6-keto-prostaglandin (PG)F1α (6-keto-PGF1a), the stable metabolite of the endothelium cyclooxygenase-derived prostacyclin.13 Moreover, the relative contribution of oxidative stress in inducing persistent abnormalities in platelet and endothelial function remains to be determined.
Here, we report the first observation that oxidative stress is increased and directly correlated with the rate of systemic TxA2 and prostacyclin biosynthesis in a group of subjects with autism compared with findings in controls.
The participants in the study were 26 children with autism who had not undergone any treatment and 12 healthy control children. The test subjects were outpatients at the Pfeiffer Treatment Center who had a diagnosis of autism on the basis of the criteria for autistic disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition and a diagnostic interview conducted by a developmental pediatrician.14,15 Children with autism were excluded from the study if they had ever been treated with antioxidants, chelators, nutritional supplements, or medications with known antioxidant effect. They were also excluded if they were sick within 2 weeks of the sample collection or if they had a chronic inflammatory disorder (such as asthma or arthritis), seizures, depression, psychosis, head injury, schizophrenia, or other mental disorders or were taking psychiatric or anti-inflammatory medications. All subjects were carefully screened for signs of infection or other illnesses on the day of specimen acquisition, and their parents attested to the absence of these potential confounders in the prior month.
The same criteria applied to all control subjects, each of whom (1) was a healthy, well-adjusted child who was not receiving any kind of therapy; (2) had no relatives with a diagnosis of autism spectrum disorder and had good behavior and academic standing; (3) had no mental disorder, including autism spectrum disorder; and (4) received no medication for at least 1 month and stopped receiving any multivitamin 2 weeks before sample acquisition. The study was approved by the institutional review board of the Pfeiffer Treatment Center, and each family provided a signed consent form authorizing their participation in the study.
Data were always analyzed in a blinded fashion. Urinary isoprostone F2a-VI (iPF2α-VI), 2,3-dinor-TxB2, and 6-keto-PGF1α were measured in urine spot samples by using standardized gas chromatography–mass spectrometry assays, as previously described. Briefly, each sample was first spiked with the corresponding deuterated internal standard, extracted by means of a solid phase extraction column, purified by means of a thin-layer chromatography step, and finally assayed by means of negative ion chemical ionization gas chromatography–mass spectrometry.16,17 A urine aliquot (0.1 mL) was used to measure creatinine concentration with a commercially available, standardized colorimetric assay (Sigma-Aldrich Co, St Louis, Mo). Results were always normalized for urinary creatinine concentration, as previously described.17
Data are presented as mean ± SEM. Statistical analysis was performed by using nonparametric 1-way analysis of variance (Kruskall-Wallis test) and Dunn posttest comparison. Correlations between variables were examined by using linear regression analysis. Only P values lower than .05 were regarded as significant.
As shown in the Table, we recruited 38 individuals: 26 subjects with autism and 12 control subjects. Although they were well matched for sex (autistic, 22 [85%] boys; controls, 10 [80%] boys), subjects with autism were younger than the controls (mean, 4.6 vs 6.7 years) (Table).
First, we compared the iPF2α-VI contents in the urine of children with autism with that of the controls. The urinary levels of iPF2α-VI were significantly higher in children with autism (5.2 ± 0.5 ng/mg creatinine) than in the controls (3.1 ± 0.3 ng/mg creatinine, P<.01) (Table). The data were also significant when children with autism were compared with the controls of the same sex (boys, 4.9 ± 0.5 vs 2.9 ± 0.4 ng/mg creatinine; girls, 6.6 ± 0.8 vs 3.5 ± 0.8 ng/mg creatinine; P<.05 for both). No significant difference in urinary creatinine levels was observed between the 2 groups of subjects (Table). No effect of age was observed on iPF2α-VI levels either in the subjects with autism or control subjects (r2 = 0.05, P = .18) (Figure 1).
Figure 2 (upper panel) illustrates the urinary levels of 2,3-dinor TxB2 in the 2 groups investigated. Similar to the findings for iPF2α-VI, 2,3-dinor TxB2 content in the urine of subjects with autism was significantly higher than that in control subjects (2.9 ± 0.2 vs 1.8 ± 0.1 ng/mg creatinine, P<.01).
Next, we investigated the endogenous biosynthesis of prostacyclin by assaying the urinary levels of its stable metabolite 6-keto-PGF1α. As shown in Figure 2 (lower panel), subjects with autism had a much higher urinary excretion of 6-keto-PGF1α than did controls (2.01 ± 0.2 vs 1.07 ± 0.3 ng/mg creatinine, P = .005).
Levels of 2,3-dinor-TxB2 directly correlated with 6-keto-PGF1α in subjects with autism (r2 = 0.22, P = .01), suggesting a common mechanism of formation. Finally, we observed a linear relationship between those 2 metabolites and urinary iPF2α-VI levels (2,3-dinor-TxB2: r2 = 0.30, P = .003; and 6-keto-PGF1α: r2 = 0.33, P = .002) (Figure 3).
The major finding of this study is that autism is characterized by increased in vivo oxidative stress, which associates and directly correlates with biochemical signatures of platelet and vascular endothelial activation.
Autism is a complex neurologic disorder; its pathogenesis involves an interaction among multiple genetic, epigenetic, and environmental factors.1-5 Oxidative imbalance is a feature of the autistic syndrome, and several lines of evidence support the hypothesis that oxidative stress also may play a functional role in this disease. Thus, autism is characterized by a lower antioxidant defense system, higher free radical production, and improvement of behavioral symptoms after antioxidant administration.6-9,18-20
Consistent with a previous report,10 our results indicated that children with autism showed higher rates of in vivo lipid peroxidation than did controls. More important, in our study, this increase was independent of the age of the subjects investigated. A subgroup of children with autism is characterized by regression, a potential confounding factor. However, we found no difference between regressed vs early-onset subgroups along the variables we measured. Moreover, we observed that girls in the autism group and in the control group did not show a significant difference in isoprostane levels when compared with levels in boys. However, this conclusion may be secondary to the relatively small size of the girls in our study. Finally, by contrast with a previous study, isoprostane levels in the subjects with autism in our study did not show a bimodal distribution.10 This difference could be due to different inclusion/exclusion criteria adopted in recruiting the subjects. Thus, by contrast with that study, the subjects with autism in our study were not taking any medication. Another possible reason is the fact that while Ming et al10 measured 8-iso-prostaglandin F2α, a class III F2-isoprostane, we assayed iPF2α-VI, a member of class VI.11 Thus, previous reports have shown that in vivo, for mechanisms not completely understood, there could be a preferential formation of one isomer vs the other of this large family.11
Measurement of iPF2α-VI has been characterized as a reliable and specific method of investigating lipid peroxidation in vivo and reflects a status of enhanced oxidative stress, regardless of the underlying pathophysiologic triggers. Interestingly, iPF2α-VI belongs to a class of lipids, the F2-isoprostanes that are also characterized by biological activities. Thus, they modulate the vascular phenotype of the oxidative stress response by inducing, among other phenomena, platelet activation and vasoconstriction.11 For this reason, we investigated the relationship between oxidative stress and the vascular phenotype in subjects with autism. This study represents the first observation, to our knowledge, that the rates of TxA2 and prostacyclin biosynthesis, markers of platelet and endothelial activation, respectively, are not only significantly increased in autism but also are closely correlated with the rate of oxidative stress.
Because F2-isoprostanes promote platelet aggregation and vasoconstriction, the correlation of these variables in our study allows some speculation about a direct effect of these bioactive lipids on the vascular phenotype in autism. However, our data do not establish a causal relationship among the variables we measured. Abnormal markers of platelet activation and vasoconstriction in autism may result from many factors, including other biologically active species resulting from free radicals.11 In general, abnormalities of the vascular phenotype can be reflected clinically by an abnormal blood flow. In this regard, it is interesting that results of multiple neuroimaging studies demonstrate brain hypoperfusion in autism.21,22 Further elucidation of the relationship of oxidative stress and vascular homeostasis to the pathogenesis of autism, including the possible influence of F2-isoprostane on tissue perfusion, could lead to improvements in therapy.
Correspondence: Domenico Praticò, MD, Department of Pharmacology, University of Pennsylvania, 3620 Hamilton Walk, John Morgan Building, Room 124, Philadelphia, PA 19104 (email@example.com).
Accepted for Publication: February 21, 2006.
Author Contributions:Study concept and design: Walsh, McGinnis, and Praticò. Acquisition of data: Praticò. Analysis and interpretation of data: Yao and McGinnis. Drafting of the manuscript: Yao and Praticò. Critical revision of the manuscript for important intellectual content: Walsh, McGinnis, and Praticò. Statistical analysis: Praticò. Obtained funding: Walsh and McGinnis. Administrative, technical, and material support: Yao, McGinnis, and Praticò. Study supervision: Walsh and Praticò.
Funding/Support: We acknowledge the financial support of Alexander and Bo MacInnis to the Pfeiffer Treatment Center.
Acknowledgment: We thank the subjects and their families, whose generosity made this research possible.